Cargando…
What neurosurgeons need to know about dabigatran etexilate (pradax(®)/pradaxa(®)/prazaxa(®))
Dabigatran etexaliate is a novel oral anticoagulant that directly inhibits thrombin. It offers a number of substantial medical benefits over other oral and parenteral anticoagulants but its advent raises important neurosurgical considerations. Dabigatran has important potential benefits. Unlike warf...
Autores principales: | Dwyer, Christopher Michael, Damodaran, Omprakash, Heckelmann, Michael, Sheridan, Mark Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421970/ https://www.ncbi.nlm.nih.gov/pubmed/25972932 http://dx.doi.org/10.4103/1793-5482.144156 |
Ejemplares similares
-
Boehringer launches first direct thrombin inhibitor: dabigatran (Pradaxa®)
Publicado: (2010) -
The Discovery of Dabigatran Etexilate
por: van Ryn, Joanne, et al.
Publicado: (2013) -
Dabigatran etexilate tetrahydrate
por: Liu, Hong-Qiang, et al.
Publicado: (2012) -
New options with dabigatran etexilate in anticoagulant therapy
por: Maegdefessel, Lars, et al.
Publicado: (2010) -
Dabigatran-etexilate: Lack of efficacy: case report
Publicado: (2021)